Immunologic Approaches for Oncolytic Viral Therapy of Prostate Cancer

2005 ◽  
Author(s):  
Robert L. Martuza
Keyword(s):  
Prostate Cancer ◽  
Oncolytic Viral Therapy ◽  
Viral Therapy

scholarly journals Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic

2010 ◽  
Vol 70 (6) ◽  
pp. 2435-2444 ◽  
Author(s):  
Chandini M. Thirukkumaran ◽  
Michael J. Nodwell ◽  
Kensuke Hirasawa ◽  
Zhong-Qiao Shi ◽  
Roman Diaz ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Oncolytic Viral Therapy ◽  
Viral Therapy

Combined suicide gene therapy and oncolytic viral therapy for prostate cancer

2002 ◽  
Vol 1 (1) ◽  
pp. 9
Author(s):  
James Young ◽  
Lawrence Young ◽  
Peter Searle ◽  
Alan Doherty ◽  
Michael Wallace ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gene Therapy ◽  
Suicide Gene ◽  
Suicide Gene Therapy ◽  
Oncolytic Viral Therapy ◽  
Viral Therapy

scholarly journals An Agent-Based Model of Combination Oncolytic Viral Therapy and Anti-PD-1 Immunotherapy Reveals the Importance of Spatial Location When Treating Glioblastoma

Cancers ◽  
2021 ◽  
Vol 13 (21) ◽  
pp. 5314
Author(s):  
Kathleen M. Storey ◽  
Trachette L. Jackson
Keyword(s):  
Three Dimensional ◽  
Spatial Location ◽  
Adaptive Strategy ◽  
Treatment Modalities ◽  
Agent Based Model ◽  
Agent Based ◽  
Oncolytic Viral Therapy ◽  
Landscape Characteristics ◽  
Adaptive Immune ◽  
Viral Therapy

Oncolytic viral therapies and immunotherapies are of growing clinical interest due to their selectivity for tumor cells over healthy cells and their immunostimulatory properties. These treatment modalities provide promising alternatives to the standard of care, particularly for cancers with poor prognoses, such as the lethal brain tumor glioblastoma (GBM). However, uncertainty remains regarding optimal dosing strategies, including how the spatial location of viral doses impacts therapeutic efficacy and tumor landscape characteristics that are most conducive to producing an effective immune response. We develop a three-dimensional agent-based model (ABM) of GBM undergoing treatment with a combination of an oncolytic Herpes Simplex Virus and an anti-PD-1 immunotherapy. We use a mechanistic approach to model the interactions between distinct populations of immune cells, incorporating both innate and adaptive immune responses to oncolytic viral therapy and including a mechanism of adaptive immune suppression via the PD-1/PD-L1 checkpoint pathway. We utilize the spatially explicit nature of the ABM to determine optimal viral dosing in both the temporal and spatial contexts. After proposing an adaptive viral dosing strategy that chooses to dose sites at the location of highest tumor cell density, we find that, in most cases, this adaptive strategy produces a more effective treatment outcome than repeatedly dosing in the center of the tumor.

scholarly journals Oncolytic Viral Therapy

2020 ◽  
Vol 42 (11) ◽  
pp. 1-9
Author(s):  
Veronica Hackethal
Keyword(s):  
Oncolytic Viral Therapy ◽  
Viral Therapy

scholarly journals ONCOLYTIC VIRAL THERAPY IN CANCER THERAPEUTICS

2017 ◽  
Vol 10 (10) ◽  
pp. 96
Author(s):  
Krishnan Vengadaragava Chary ◽  
Anish Bharatwaj
Keyword(s):  
Clinical Trial ◽  
Meta Analysis ◽  
Cancer Therapeutics ◽  
Drug Approval ◽  
Clinical Trial Registry ◽  
Oncolytic Viral Therapy ◽  
Medical College ◽  
Comprehensive Information ◽  
Viral Therapy ◽  
The Us

Objective: The aim of this study is to provide comprehensive information of oncolytic viral therapy, from the origin to present scenario.Methods: This observational study was conducted by the Department of Pharmacology, Saveetha Medical College, Chennai between July and December 2016. Date regarding ongoing oncolytic virotherapy trials was retrieved from clinical trial database, United States and Clinical trial registry forum, India. Tamilnogene approval details were obtained from the US-Food and Drug Administration approval new drug approval information.Results: Eleven ongoing trials in Phase I and Ia are being carried out, of which 4 viral strains such as herpes, adenovirus, measles, and reovirus are used for intracerebral malignancies. Four trials have shown superior effects and seven trial results are yet to be completed.Conclusion: Oncolytic viral therapy can be as effective as targeted therapy in battling against cancer; however, long-term efficacy and safety should be established from more studies and meta-analysis.

scholarly journals HG-22TREATMENT OF INTRA-BRAIN STEM XENOGRAFT MOUSE MODELS OF DIPG WITH COMBINED RADIATION AND ONCOLYTIC VIRAL THERAPY

2016 ◽  
Vol 18 (suppl 3) ◽  
pp. iii52.2-iii52
Author(s):  
Yuchen Du ◽  
Huiyuan Zhang ◽  
Lin Qi ◽  
Holly Lindsay ◽  
Mari Kogiso ◽  
...  
Keyword(s):  
Brain Stem ◽  
Mouse Models ◽  
Oncolytic Viral Therapy ◽  
Viral Therapy
Sign in / Sign up

Export Citation Format

Share Document